DNTH Stock: Price, Earnings History and SEC Filings
Dianthus Therapeutics, Inc. (DNTH) last traded at $82.38, down 0.39% on the latest session and down 6.4% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $-0.90 against an analyst estimate of $-0.93, a beat of 3.2%.
$82.38 -0.39%
1 month-6.44%
52-week high$117.88
52-week low$32.28
Volume496,893
ExchangeNasdaqCM
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
DNTH earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Aug 4, 2026 | $-0.90 | $-0.93 | +3.23% |
| Mar 2026 | May 5, 2026 | $-0.85 | $-1.17 | +27.35% |
| Dec 2025 | Mar 9, 2026 | $-1.43 | $-0.98 | -45.92% |
| Sep 2025 | Nov 5, 2025 | $-0.97 | $-0.86 | -12.79% |
DNTH beat the analyst EPS estimate in 2 of its last 4 reported quarters. Source: Nasdaq.
DNTH financial history
Revenue
Net income
Free cash flow
| Fiscal year | Revenue | Net income | Free cash flow | Net margin | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | $2M | -$162M | – | -7973.3% | $-4.20 |
| 2024 | $6M | -$85M | – | -1362.8% | $-2.55 |
| 2023 | $3M | -$44M | – | -1541.2% | $-8.45 |
| 2019 | $0 | -$77M | -$60M | – | – |
| 2018 | $0 | -$58M | -$50M | – | – |
| 2017 | $0 | -$35M | -$24M | – | – |
| 2016 | $0 | -$9M | -$7M | – | – |
Source: annual figures from 10-K filings on SEC EDGAR. The year shown is the calendar year the fiscal year ended. Free cash flow is operating cash flow minus capital spending.
Latest SEC filings for DNTH
SEC filing data is not available right now. You can search for DNTH on SEC EDGAR.
DNTH news
- Regeneron (REGN) Q3 Earnings and Revenues Beat EstimatesOct 30, 2026 · finance.yahoo.com
- Halozyme Therapeutics (HALO) Reports Next Week: Wall Street Expects Earnings GrowthOct 29, 2026 · finance.yahoo.com
- Dianthus Therapeutics (DNTH) Stock May Be Above Fair Value Following Its 5x RunOct 20, 2026 · finance.yahoo.com
About Dianthus Therapeutics, Inc.
Dianthus Therapeutics, Inc. (DNTH) is a US-listed public company on Nasdaq.